source
- STAT+: FDA rejects lung cancer treatment ivonescimab from Summit TherapeuticsThe FDA has rejected ivonescimab, a treatment for a type of lung cancer developed by U.S. biotech Summit Therapeutics and the Chinese drugmaker Akeso.STAT · 5h ago↗ source
- HHS to allocate up to $4.9 million for ibogaine research targeting PTSDThe U.S. Department of Health and Human Services announced it will provide up to $4.9 million to support research on ibogaine, a psychedelic compound. The funding is intended to explore ibogaine’s…